(RTTNews) - Zai Lab (ZLAB) and Novocure (NVCR) announced that the Phase 3 PANOVA-3 trial met its primary endpoint, showing a statistically significant improvement in median overall survival versus control. PANOVA-3 evaluated the use of Tumor Treating Fields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
Novocure plans to file for regulatory approval of TTFields in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3. Zai Lab plans to file for regulatory approval in China.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
